Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.

Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

cohort study in 1st-episode schizophrenia: The effectiveness of antipsychotics for relapse prevention decreased after the 2nd relapse. The aHR for rehospitalisation with AP use versus non-use increased from 0·42 to 0·78 after the 2nd relapse (p<0·0001) https://t.co/IBhDPNJJpe?

— PfOL (@psychopharmacol) March 18, 2022